Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis.

Curr Oncol · 2023 · PMC10528081 · PMID 37754530

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Among the other chemotherapy-containing regimens compared to Chem alone, we observed an increasing trend in OS benefit for HR+/HER2+MBC patients, but no significant differences were found ( Figure S7 ).

also in 63,971 other papers

did not reach statistical significanceno p-value reported

However, these results did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.